ResMed (ASX:RMD) Land And Improvements: A$76 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:RMD ResMed Inc ASX:RMD
97 GF Score
Price A$31.68
GF Value A$37.42
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Land And Improvements?

ResMed ASX:RMD -1.28% 97 Land And Improvements is A$76 Mil as of Jun. 2026. GuruFocus rates ASX:RMD with a GF Score™ of 97/100 and a GF Value™ of A$37.42 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ResMed's land and improvements for the quarter that ended in Jun. 2026 was A$76 Mil.

ResMed's quarterly land and improvements stayed the same from Dec. 2025 (A$0 Mil) to Mar. 2026 (A$0 Mil) but then increased from Mar. 2026 (A$0 Mil) to Jun. 2026 (A$76 Mil).

ResMed's annual land and improvements increased from Jun. 2024 (A$78 Mil) to Jun. 2025 (A$79 Mil) but then declined from Jun. 2025 (A$79 Mil) to Jun. 2026 (A$76 Mil).

ResMed Land And Improvements Historical Data

* Premium members only.

The historical data trend for ResMed's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Land And Improvements Chart

ResMed Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Land And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.80 77.56 78.28 79.38 76.23

ResMed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.38 0.00 0.00 0.00 76.23
ASX:RMD
97GF Score
ResMed Inc ASX:RMD
Land And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Frequently Asked Questions Learn more about Land And Improvements →
What does a Land And Improvements of A$76 Mil mean?
ResMed (ASX:RMD) has a Land And Improvements of A$76 Mil as of Jun. 2026. Land and improvements records the total value of a company's land and improvements to it. View historical data on ResMed and its competitors.
Is ResMed's Land And Improvements too high?
ResMed's current Land And Improvements is A$76 Mil. Overall, ResMed has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Land And Improvements compare to MDLN and WST?
ResMed's Land And Improvements of A$76 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Land And Improvements for a Medical Devices & Instruments company?
A good Land And Improvements depends on the Medical Devices & Instruments industry context. However, Land And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Land And Improvements mean?
A high Land And Improvements can signal that a stock is expensive relative to its fundamentals. Land and improvements records the total value of a company's land and improvements to it. View historical data on ResMed and its competitors. ResMed's current Land And Improvements is A$76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (ASX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is A$37.42, compared to a current price of A$31.68 — trading 15.3% below its estimated fair value. The current Land And Improvements is A$76 Mil. ResMed's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Land And Improvements calculated?
Land And Improvements is calculated from a company's financial statements. For ResMed (ASX:RMD), the current Land And Improvements is A$76 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (ASX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of A$31.68 is trading 15.3% below its estimated GF Value™ of A$37.42. GuruFocus considers ResMed to be Modestly Undervalued.

Key valuation signals for ASX:RMD:

  • Land And Improvements: A$76 Mil
  • GF Value™: A$37.42 vs. price of A$31.68 (15.3% below fair value)
  • GF Score™: 97/100 with 1 warning sign

No single metric tells the full story. See the ASX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
97GF Score

Get the complete analysis for ASX:RMD

Land And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$31.68
Price
A$37.42
GF Value